Jane Street Group, LLC Bio Atla, Inc. Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

A detailed history of Jane Street Group, LLC transactions in Bio Atla, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 49,087 shares of BCAB stock, worth $84,429. This represents 0.0% of its overall portfolio holdings.

Number of Shares

49,087

Previous 136,701 64.09%

Holding current value

$84,429

Previous $187,000 54.01%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.17 - $2.05 $102,508 - $179,608	-87,614 Reduced 64.09%	49,087 $86,000
Q2 2024 Aug 14, 2024	BUY	$1.37 - $3.92 $187,280 - $535,867	136,701 New	136,701 $187,000
Q4 2023 Feb 14, 2024	BUY	$1.27 - $3.18 $148,588 - $372,056	116,999 New	116,999 $287,000
Q2 2023 Aug 14, 2023	SELL	$2.83 - $3.87 $183,137 - $250,439	-64,713 Reduced 56.19%	50,450 $151,000
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $136,300 - $488,903	59,261 Added 106.01%	115,163 $308,000
Q4 2022 Feb 14, 2023	BUY	$6.29 - $11.01 $271,331 - $474,938	43,137 Added 337.93%	55,902 $461,000
Q3 2022 Nov 14, 2022	SELL	$2.94 - $11.87 $31,211 - $126,011	-10,616 Reduced 45.4%	12,765 $98,000
Q2 2022 Aug 16, 2022	SELL	$2.13 - $5.38 $37,594 - $94,957	-17,650 Reduced 43.02%	23,381 $67,000
Q1 2022 May 17, 2022	BUY	$4.38 - $18.78 $179,715 - $770,562	41,031 New	41,031 $205,000
Q4 2021 Feb 15, 2022	SELL	$19.0 - $30.95 $152,893 - $249,054	-8,047 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$29.44 - $43.74 $236,903 - $351,975	8,047 New	8,047 $237,000
Q2 2021 Aug 16, 2021	SELL	$38.07 - $56.17 $267,517 - $394,706	-7,027 Closed	0 $0
Q1 2021 May 18, 2021	BUY	$32.41 - $70.91 $227,745 - $498,284	7,027 New	7,027 $357,000

Others Institutions Holding BCAB

# of Institutions

Shares Held

17.3M

Call Options Held

500

Put Options Held

33.5K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Bio Atla, Inc. Transaction History